Replies to post #3982 on Halozyme Therapeutics Inc (HALO)

[DewDiligence]

Hard to say because I know a lot more about MNTA than I do about HALO. The overlap between the companies is actually very small; both have programs in second-line pancreatic cancer, but this is way down on the list of value drivers for MNTA, IMO.